Article
Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
European journal of cancer (Oxford, England : 1990) - 1 Sept 2018
Ben-Betzalel Guy, Baruch Erez N, Boursi Ben, Steinberg-Silman Yael, Asher Nethanel, Shapira-Frommer Ronnie, Schachter Jacob, Markel Gal
Abstract excerpt
BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) are among the cornerstones of metastatic melanoma therapy demonstrating excellent response rates with duration of 7-12 m. Long-term benefit from these agents was reported in patients with normal lactate dehydrogenase (LDH) and less than three disease sites. However, a treatment-dependent marker for long-term efficacy is lacking. Data suggest that immune-related...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.